BioMarin gene therapy shows sustained benefit in hemophilia A study

BioMarin Pharmaceutical (NASDAQ:BMRN) announces updated data from an open-label Phase 1/2 clinical trial evaluating a single administration of gene therapy valoctocogene roxaparvovec in adults with severe hemophilia A. The results will be virtually presented at the World Federation of Hemophilia Summit June 14-19.